CHF 2.885 after hours: RLF.SW Relief Therapeutics (SIX) Mar 2026 oversold bounce

We see RLF.SW stock trading at CHF 2.885 in after-hours trade on 20 Mar 2026, up 0.87% on the day. Volume finished at 66,704 shares, above the 50-day average of 41,210, which supports an oversold bounce thesis. The stock remains below its 52-week high of CHF 4.59 and above its 52-week low of CHF 1.65. We link recent clinical updates and sector pressure to the price move and outline tactical trade levels for short-term buyers

Price action and set-up: RLF.SW stock

RLF.SW stock closed the session at CHF 2.885, up CHF 0.025 from the previous close. Intraday range ran between CHF 2.80 and CHF 3.00, showing a tight bounce after recent selling. Relative volume of 1.62 signals above average participation. The 50-day average is CHF 2.91 and the 200-day average is CHF 2.61, which places the current price near near-term technical support and a potential short-term reversal zone

Fundamentals snapshot for RLF.SW stock

Relief Therapeutics reports EPS -1.36 and a trailing PE of -2.12, reflecting ongoing clinical-stage losses. Book value per share is CHF 2.60 and price-to-book is 1.11. Market capitalization stands at CHF 36.28 million. The company holds cash per share CHF 0.99 and a strong current ratio of 4.05, which reduces immediate liquidity risk despite negative earnings

Clinical news and catalysts affecting RLF.SW stock

Relief’s lead program RLF-100 (aviptadil) remains the key catalyst. Upcoming earnings and trial updates can swing sentiment. A planned earnings announcement on 08 Apr 2026 could reprice risk. Recent press coverage referenced trials and regulatory interest. We note clinical readouts often drive volatile moves for biotechnology names listed on the SIX exchange in Switzerland

Technical levels and oversold bounce trade for RLF.SW stock

For traders, a simple setup is to watch CHF 2.60–2.80 as a support band and CHF 3.40 as first resistance. A close above CHF 3.40 on higher volume would validate a measured move toward CHF 4.00. Stop placement below CHF 2.60 limits downside. The stock posted a 3-month gain of 7.25%, but one-year performance is down 27.15%, so expect volatility

Meyka Grade and analyst context for RLF.SW stock

Meyka AI rates RLF.SW with a score of 64.68 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Independent company ratings also show mixed views; a third-party company rating dated 28 Feb 2025 gives a C / Sell. We present both the Meyka grade and external ratings to show the divergence between model signals and market sentiment

Valuation, sector comparison and risks for RLF.SW stock

Biotech peers in Healthcare trade at higher multiples; sector average PE is about 27.01 while Relief carries a negative PE. Price-to-book of 1.11 is lower than many development-stage peers. Key risks include trial failure, dilution from capital raises, and low liquidity. The stock’s average daily volume of 41,210 can widen spreads on entries and exits

Final Thoughts

Meyka AI’s forecast model projects medium-term upside for Relief Therapeutics but flags clinical risk. Our model shows a 5-year central forecast of CHF 4.86, versus the current after-hours price of CHF 2.885, implying a theoretical upside of 68.44%. That projection is model-based and not a guarantee. Near term, the oversold bounce is tradable with tight risk controls. We prefer a tactical approach: fade weakness into CHF 2.60–2.80, add on a verified positive catalyst, and use stops below CHF 2.60. Remember the company reports negative EPS -1.36 and a small market cap CHF 36.28 million, so position sizes should reflect high volatility and event risk. Meyka AI provides this as data-driven market analysis, not financial advice

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.